Alazocine
From Wikipedia, the free encyclopedia
(Redirected from SKF-10047)
Jump to: navigation, search
![]() |
|
Clinical data | |
---|---|
Routes of administration |
? |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
ChemSpider |
|
ChEMBL | |
ECHA InfoCard | 100.162.264 |
Chemical and physical data | |
Formula | C17H23NO |
Molar mass | 257.37 g/mol |
3D model (Jmol) | |
|
|
|
|
![]() ![]() |
Alazocine ((-)-SKF-10,047), or (-)-N-allylnormetazocine ((-)-ANMC), was the first drug discovered to act as a σ1 receptor agonist (Ki = 24 nM).[1][2][3] It has no significant affinity for the σ2 receptor.[3] Alazocine also acts as a κ-opioid receptor partial agonist (Ki = 0.4 nM; EC50 = 24 nM; Emax = 66%),[4] and to a much lesser extent, as an NMDA receptor antagonist (Ki = 587 nM).[3][5]
See also[edit]
References[edit]
- ^ Iwamoto ET (February 1981). "Pharmacologic effects of N-allylnormetazocine (SKF-10047)". NIDA Research Monograph. 34: 82–8. PMID 6783955.
- ^ Shearman GT, Herz A (August 1982). "Non-opioid psychotomimetic-like discriminative stimulus properties of N-allylnormetazocine (SKF 10,047) in the rat". European Journal of Pharmacology. 82 (3–4): 167–72. PMID 6290235. doi:10.1016/0014-2999(82)90506-4.
- ^ a b c Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (March 1999). "Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan". Brain Research. 821 (2): 516–9. PMID 10064839. doi:10.1016/S0006-8993(99)01125-7.
- ^ Gharagozlou, Parham; Hashemi, Ezzat; DeLorey, TimothyM; Clark, J David; Lameh, Jelveh (2006). "Pharmacological profiles of opioid ligands at Kappa opioid receptors". BMC Pharmacology. 6 (1): 3. ISSN 1471-2210. PMC 1403760
. PMID 16433932. doi:10.1186/1471-2210-6-3.
- ^ Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J (2006). "Pharmacological profiles of opioid ligands at Kappa opioid receptors". BMC Pharmacology. 6 (1): 3. PMC 1403760
. PMID 16433932. doi:10.1186/1471-2210-6-3.
Receptor (ligands) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (blockers) |
|
||||||||||||||||||||||||||
Enzyme (inhibitors) |
|
||||||||||||||||||||||||||
Others |
|
||||||||||||||||||||||||||
MOR |
|
---|---|
DOR |
|
KOR |
|
NOP |
|
Unsorted | |
Others |
|
σR |
|
---|---|
See also: Receptor/signaling modulators
|
![]() |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=Alazocine&oldid=785078750"
Hidden categories:
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- ECHA InfoCard ID from Wikidata
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- All stub articles